NYSE · DGX
Healthcare · Medical - Diagnostics & Research
$251.82
Down-$1.10 (-0.43%)
Updated Nov 1, 2026, 3:01 PM
SID Score
6.8/10
Composite research score
Smart Money
47/100
Neutral
Price performance · DGX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
DGX closed at $251.82 after 20 trading sessions, up 8.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $255.14 | $256.99 | $250.9526 | $251.82 | 919.59K |
| Oct 29, 2026 | $246.25 | $253.12 | $245.40 | $252.92 | 946.28K |
| Oct 28, 2026 | $242.96 | $249.73 | $242.34 | $245.62 | 932.8K |
| Oct 27, 2026 | $241.96 | $243.265 | $239.59 | $242.56 | 919.02K |
| Oct 26, 2026 | $243.00 | $244.215 | $240.98 | $242.95 | 959.62K |
| Oct 23, 2026 | $239.63 | $244.33 | $239.63 | $241.89 | 933.38K |
| Oct 22, 2026 | $226.50 | $246.00 | $226.22 | $243.28 | 1.69M |
| Oct 21, 2026 | $235.34 | $240.56 | $223.50 | $238.93 | 1.21M |
| Oct 20, 2026 | $236.00 | $237.29 | $234.06 | $237.12 | 1.1M |
| Oct 19, 2026 | $234.40 | $235.99 | $233.82 | $234.91 | 864.65K |
| Oct 16, 2026 | $239.67 | $240.7499 | $233.56 | $235.00 | 799.65K |
| Oct 15, 2026 | $235.85 | $239.17 | $235.57 | $239.15 | 1M |
| Oct 14, 2026 | $231.32 | $234.97 | $231.32 | $233.43 | 1.2M |
| Oct 13, 2026 | $233.13 | $234.33 | $230.23 | $230.46 | 1.01M |
| Oct 12, 2026 | $228.66 | $234.6399 | $228.66 | $232.63 | 865.23K |
| Oct 9, 2026 | $227.86 | $232.18 | $227.86 | $230.97 | 775.46K |
| Oct 8, 2026 | $228.16 | $231.08 | $226.36 | $230.81 | 941.88K |
| Oct 7, 2026 | $228.51 | $229.80 | $226.81 | $227.06 | 927.43K |
| Oct 6, 2026 | $229.92 | $232.09 | $225.78 | $228.39 | 1.78M |
| Oct 5, 2026 | $232.93 | $233.65 | $229.955 | $232.22 | 1.01M |
The latest Smart Investors Daily articles mentioning DGX.
Company
Market Activity
Research & News
DGX research
Company profile and research snapshot.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 21, 2026 | Truist Securities | Hold | — |
| Sep 8, 2026 | UBS | Neutral | — |
| Jul 28, 2026 | JP Morgan | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 30, 2026
The testing service providers hope the legislation, which would reform the CMS’ reimbursement rate-setting process, can cross the finish line in Congress’ lame-duck session.
Yahoo · Oct 28, 2026
For questions about this article or underlying research, email [email protected].
Yahoo · Oct 27, 2026
DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on profitability.
SeekingAlpha · Oct 26, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DGX.
